Author Archives: Millie Nelson

PerkinElmer teams with CRG for diabetes gene therapy

PerkinElmer acquisition Sirion Biotech has partnered with the Center for Genomic Regulation (CRG) in Barcelona, Spain to develop adeno-associated virus (AAV) vectors for type 1 and 2 diabetes. Viral vector-based gene therapy firm Sirion (acquired by PerkinElmer in June 2021) will use its AAV technology platform alongside international biomedical research center CRG‚Äôs knowledge of genetic regulatory mechanisms. The goal of the partnership is to create AAV vectors that target specific pancreatic cell types and contain payloads that express therapeutic genes…

Cytiva to build first oligo FlexFactory for Chinese CDMO

Chinese drugmaker General Biol has chosen Cytiva’s single-use Flex-Factory platform to support oligonucleotide production. The deal, of which financial details have not been disclosed, sees Cytiva provide General Biol with its integrated FlexFactory single-use ¬†platform. This includes an OligoProcess nucleic acid synthesis system, √ĄKTA Process explosion-proof purification system, and a Uniflux explosion-proof tangential flow ultrafiltration system. ‚ÄúA FlexFactory is a biomanufacturing platform that supports different types of manufacturing processes,‚ÄĚ a spokesperson for Cytiva told us. ‚ÄúIt is configurable with respect…

Polyplus adds DNA services with e-Zyvec buy

Through the acquisition of DNA design and production services firm e-Zyvec, Polyplus will expand its plasmid DNA vector engineering offerings. The French biotech would not disclose any financial details of the deal but told BioProcess Insider the acquisition ‚Äúcritical to execute Polyplus‚Äô¬†portfolio diversification¬†strategy by acquiring plasmid DNA (pDNA) engineering capability that will provide synergies to our customers in terms of process efficiency.‚ÄĚ Polyplus claims to be the market leader in transfection reagents for gene therapy viral vector manufacturing and through…

Takeda and Code Bio team up to make gene therapies

The partnership will see Code Bio‚Äôs 3DNA platform used to design and develop gene therapies for rare disease indications. Under the terms of the deal, Takeda will use Code Biotherapeutics‚Äô (Code Bio‚Äôs) non-viral 3DNA platform to target a liver-directed rare disease program and central nervous system conditions across a total of four programs. ‚Äú3DNA is a synthetically made DNA that can be used as a targeted vehicle to deliver therapies.¬† We have a proprietary process to attach therapeutic payloads and…

Catalent’s incoming CEO ready to stand on the shoulders of giants

BioProcess Insider had the pleasure of figuratively sitting down with Catalent‚Äôs chief operating officer Alessandro Maselli who is set to succeed John Chiminski as CEO effective July 1, 2022. If you know anything about the contract development manufacturing organization (CDMO) space, you know about John Chiminski. He joined Catalent in 2009 and has since led the firm through a period of evolution ‚Äď taking it from a traditional softgel and small molecule service provider to a strategic partner working across…

Moderna in talks to open UK mRNA plant

Moderna is reportedly eyeing up the UK as its next location for an mRNA manufacturing and research facility. Moderna has already laid down plans for messenger RNA (mRNA) manufacturing facilities in Australia, Canada and Africa. Now, the Financial Times (FT) has reported that the US firm, which sprang to the forefront of biopharma on the back of the success of its COVID-19 vaccine, is in ‚Äúlate discussions‚ÄĚ with the UK government to build a plant and collaborate with the NHS…

Lilly goes big on RNA research with $700m Boston plant

Through the construction of a $700 million site in the Boston Seaport area, Eli Lilly aims to advance RNA based therapeutics. The facility, which will be known as the Lilly Institute for Genetic Medicine is part of the firm‚Äôs strategy to develop RNA based therapeutics using DNA-based technologies that can treat or prevent diseases that is difficult or not possible with traditional medicines. “The Institute will pair cutting-edge technologies with Lilly‚Äôs deep biological expertise in neuroscience, immunology, diabetes, and other…

Recipharm bolsters biologics biz with Vibalogics buy

Through the acquisition of Vibalogics, Recipharm will expand its advanced therapy medicinal products (ATMPs) offering into virotherapies. The deal, of which financial details have not been disclosed, sees Swedish contract development manufacturing organization (CDMO) Recipharm acquire Vibalogics, a virotherapy CDMO. According to Recipharm, the deal expands their capabilities in biologics modalities and Vibalogics‚Äô knowledge in viral vaccines, oncolytic viruses, and gene therapies will provide the firm with diverse technologies. ‚ÄúWe are delighted to welcome our new colleagues from Vibalogics to…

Paper is the enemy of scale in CGT manufacturing, says Ori Biotech

Ori Biotech says its paperless platform eliminates waste and reduce costs, which could potentially improve patient access to cell therapies. The London-based firm Ori Biotech formed in 2019 with a main goal of enabling extensive patient access for CGT therapies through its scalable bioreactor and fluid handling platform, which hopes to to automate, digitize, and standardize CGT production. The platform remains in stealth mode. However, this has not put off investors who backed the company‚Äôs $100 million Series B funding…

BioNTech introduces modular mRNA plan for Africa plant

BioNTech has introduced a container solution for its mRNA manufacturing strategy to improve vaccine supply in Africa. The German biotech signed a memorandum of understanding (MoU) with the Rwandan government and Institut Pasteur de Dakar in Senegal in October 2021 to start building a messenger RNA (mRNA) plant this summer. This week, in what the firm dubbed a ‚Äúhigh-level‚ÄĚ meeting at its Marburg, Germany facility, BioNTech presented a container solution named BioNTainer to various key partners. A BioNTainer is a…